Adcendo ApSDanish ADC maker Adcendo ApS has licenced the rights to commercialise Multitude Therapeutics Inc’s first-in-class ADCE-T02 globally except the Greater China region.
Tag Archive for: Novo Holdings
Draupnir Bio ApSTargeted protein degradation Draupnir Bio Aps has raised further €12m in an equitiy investment to advance its preclinical pipeline.
Forbion BioEconomy represents a strategic expansion of Forbion’s investment scope in biotech and in the life sciences sector to address challenges relating to the environment, the growing need for a sustainable supply of food and the rapid depletion of natural resources.